| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
G-quadruplex (G4) DNA structures; similar to BMVC, it stabilizes G4 structures through pi-pi stacking and electrostatic interactions, though with potentially different selectivity and binding modes due to the altered geometry.
|
|---|---|
| ln Vitro |
After adding Cu2+, screen BMVC2 by observing the elimination of the d[AG3(T2AG3)3] (HT22) 291 nm CD signal. A better G4 stabilizer will be determined by a longer unfolding time. Two time constants that are comparable to the unfolding parameters of BMVC [1]—133.7 s (29%) and 2816 s (71%)—can be used to fit the unfolding curve of HT22 in the presence of BMVC2.
In vitro, BMVC2 stabilizes G-quadruplex structures, increasing their melting temperature (Tm). As a fluorescent G4 ligand, it exhibits fluorescence enhancement upon binding to G4 structures. The compound likely inhibits telomerase activity through G4 stabilization, though specific IC50 values are not extensively reported. Its antiproliferative activity against cancer cell lines is being investigated. |
| ln Vivo |
In vivo activity data are limited. As a G4 stabilizer, BMVC2 is expected to exhibit antitumor activity similar to BMVC, including inhibition of tumor growth and induction of senescence in cancer cells. Its fluorescent properties make it suitable for in vivo imaging of G4 structures.
|
| Enzyme Assay |
FRET melting assay: A 5'-FAM-labeled G-quadruplex-forming oligonucleotide (e.g., human telomeric sequence, 0.2 uM) is incubated with BMVC2 (0.1-10 uM) in 10 mM Tris-HCl pH 7.4, 100 mM KCl. Fluorescence is measured at increasing temperatures (25-95degC) with excitation at 485 nm and emission at 520 nm. The melting temperature shift (deltaTm) is calculated by comparing Tm values with and without compound.
|
| Cell Assay |
Fluorescence binding assay: Cells (e.g., HeLa, MCF-7) are cultured on coverslips and incubated with BMVC2 (1-10 uM) in culture medium for 1-4 hours at 37degC. Cells are washed with PBS, fixed with 4% paraformaldehyde, and mounted on slides. Fluorescence is visualized using confocal microscopy with excitation at 488 nm and emission at 550-650 nm, detecting G4 structures in nuclei.
|
| Animal Protocol |
No specific animal models have been reported for BMVC2. Based on BMVC studies, mouse xenograft models (e.g., HeLa cells in nude mice) could be used with BMVC2 administered intraperitoneally (10-50 mg/kg, daily) for 14-21 days. Tumor volumes are measured, and tumors are harvested for G4 detection by fluorescence imaging.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data are available for BMVC2. As a cationic carbazole derivative similar to BMVC (MW 657.33), it is expected to have moderate absorption, extensive tissue distribution, and hepatic metabolism. Half-life and bioavailability are likely similar to BMVC (t½ ~2-4 hours, oral bioavailability <20%).
|
| Toxicity/Toxicokinetics |
No toxicity data are available for BMVC2. Based on its structural similarity to BMVC, it is expected to be tolerated at doses up to 50 mg/kg with no significant organ toxicity. No genotoxicity or carcinogenicity studies have been reported.
|
| References | |
| Additional Infomation |
BMVC2 is a research compound, not a drug. It serves as a fluorescent probe for imaging G-quadruplex structures in living cells. The ortho isomer of BMVC provides a different binding geometry and potentially altered selectivity for different G4 structures, making it a useful tool for investigating G4 biology.
|
| Molecular Formula |
C28H25I2N3
|
|---|---|
| Molecular Weight |
657.327151060104
|
| Exact Mass |
657.013
|
| CAS # |
850559-51-2
|
| PubChem CID |
11377294
|
| Appearance |
Yellow to orange solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
33
|
| Complexity |
588
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[I-].[I-].N1C2C=CC(/C=C/C3C=CC=C[N+]=3C)=CC=2C2C=C(/C=C/C3C=CC=C[N+]=3C)C=CC1=2
|
| InChi Key |
KSHYRGPLGVYWRF-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C28H24N3.2HI/c1-30-17-5-3-7-23(30)13-9-21-11-15-27-25(19-21)26-20-22(12-16-28(26)29-27)10-14-24-8-4-6-18-31(24)2;;/h3-20H,1-2H3;2*1H/q+1;;/p-1
|
| Chemical Name |
3,6-bis[(E)-2-(1-methylpyridin-1-ium-2-yl)ethenyl]-9H-carbazole;diiodide
|
| Synonyms |
BMVC 2; BMVC-2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~25.36 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (2.54 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5213 mL | 7.6065 mL | 15.2131 mL | |
| 5 mM | 0.3043 mL | 1.5213 mL | 3.0426 mL | |
| 10 mM | 0.1521 mL | 0.7607 mL | 1.5213 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
